University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Arie Perry, M.D.

Neuropathologist

Dr. Arie Perry, director of Neuropathology at UCSF Medical Center, specializes in brain tumor pathology and genetics. He also maintains an international consult service for challenging cases involving brain tumor diagnosis. His research focuses on biomarker development for enhanced diagnosis, prognostic accuracy and management of brain tumor patients.

Perry received a medical degree and pathology residency training at the University of Texas, Southwestern in Dallas, followed by fellowships in surgical pathology and neuropathology at the Mayo Clinic in Rochester, Minn. He is a member of several professional organizations, including the American Association of Neuropathologists, International Society of Neuropathology, U.S. and Canadian Association of Pathology and the Society for Neuro-Oncology. He is the recipient of numerous teaching awards and has authored various publications, including the textbook, "Practical Surgical Neuropathology." He is a professor of pathology and neurosurgery at UCSF and director of the Neuropathology Fellowship Training Program.

Conditions & Treatments

More about Arie Perry

Education

University of Texas Southwestern Medical School 1990

Residencies

University of Texas Hospital, Dallas, Pathology 1994

Fellowships

Mayo Clinic, Rochester, Minn., Surgical Pathology, Neuropathology 1998

Selected Research and Publications

  1. Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM, Phillips JJ, Vogel H, Wiencke JK, Wrensch MR, Walsh KM, Perry A. CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II-III) Astrocytomas. J Neuropathol Exp Neurol. 2015 May; 74(5):442-52.
  2. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015 May; 129(5):669-78.
  3. Rodriguez FJ, Schniederjan MJ, Nicolaides T, Tihan T, Burger PC, Perry A. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol. 2015 Apr; 129(4):609-10.
  4. Okimoto RA, Perry A, Rubenstein JL. 77-year-old woman with a dural-based mass. Brain Pathol. 2015 Jan; 25(1):111-2.
  5. Alexandrescu S, Orengo JP, Toossi S, Perry A, Treseler P, Hess C, Margeta M. CNS intravascular large cell lymphoma in a patient with autoimmune hemolytic anemia. Neuropathology. 2014 Nov 6.
  6. Tanboon J, Pongpaibul A, Chawalparit O, Wasinrat J, Witthiwej T, Perry A. A 53-year-old woman with progressive headaches. Brain Pathol. 2014 Nov; 24(6):679-80.
  7. Hainfellner J, Louis DN, Perry A, Wesseling P. Letter in Response to David N. Louis et?al, International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading, Brain Pathology, doi: 10.1111/bpa.12171. Brain Pathol. 2014 Nov; 24(6):671-2.
  8. Ud Din N, Pekmezci M, Javed G, Horvai AE, Ahmad Z, Faheem M, Navarro AL, López-Terrada D, Perry A. Low-grade small round cell tumor of the cauda equina with EWSR1-WT1 fusion and indolent clinical course. Hum Pathol. 2015 Jan; 46(1):153-8.
  9. Pekmezci M, Perry A. Genetic markers in adult high-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):235-9.
  10. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P. International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014 Sep; 24(5):429-35.
  11. Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, Martinez D, Perry A, Lewis PW, Thompson CB, Judkins AR. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014 Nov; 128(5):743-53.
  12. Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A, Horvai AE, Perry A. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol. 2015 Feb; 28(2):187-200.
  13. Reis GF, Perry A. A 67-year-old man with a lumbar spine lesion. Brain Pathol. 2014 Sep; 24(5):547-8.
  14. de Kock L, Sabbaghian N, Druker H, Weber E, Hamel N, Miller S, Choong CS, Gottardo NG, Kees UR, Rednam SP, van Hest LP, Jongmans MC, Jhangiani S, Lupski JR, Zacharin M, Bouron-Dal Soglio D, Huang A, Priest JR, Perry A, Mueller S, Albrecht S, Malkin D, Grundy RG, Foulkes WD. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol. 2014 Oct; 128(4):583-95.
  15. Yu JP, Wilson DM, Chang EF, Cotter J, Perry A, Mahindra A, Glastonbury CM. Isolated intracerebral light chain deposition disease: novel imaging and pathologic findings. Clin Imaging. 2014 Nov-Dec; 38(6):868-71.
  16. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90.
  17. Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol. 2014 Jul; 16(7):914-23.
  18. Ali S, Joseph NM, Perry A, Barajas RF, Cha S. Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant. J Neurooncol. 2014 Sep; 119(2):353-60.
  19. Spence T, Sin-Chan P, Picard D, Barszczyk M, Hoss K, Lu M, Kim SK, Ra YS, Nakamura H, Fangusaro J, Hwang E, Kiehna E, Toledano H, Wang Y, Shi Q, Johnston D, Michaud J, La Spina M, Buccoliero AM, Adamek D, Camelo-Piragua S, Peter Collins V, Jones C, Kabbara N, Jurdi N, Varlet P, Perry A, Scharnhorst D, Fan X, Muraszko KM, Eberhart CG, Ng HK, Gururangan S, Van Meter T, Remke M, Lafay-Cousin L, Chan JA, Sirachainan N, Pomeroy SL, Clifford SC, Gajjar A, Shago M, Halliday W, Taylor MD, Grundy R, Lau CC, Phillips J, Bouffet E, Dirks PB, Hawkins CE, Huang A. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014 Aug; 128(2):291-303.
  20. Pekmezci M, Vlodavsky E, Perry A. Previously unrecognized pattern of central nervous system hemangiopericytoma with pseudoglandular spaces. Clin Neuropathol. 2014 May-Jun; 33(3):186-9.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.